Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 39
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
IUBMB Life ; 73(5): 800-810, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33715293

RESUMEN

BACKGROUND: Children with ß-thalassemia major (ß-TM) suffer from tubular dysfunction even before the onset of any renal impairment symptoms and/or clinical signs. Therefore, identifying innovative biomarkers allowing early renal damage detection has focused attention. AIM: This study aims to preliminary assess Netrin-1(NTN-1) and clusterin (CLU) in ß-TM children and explore their possible roles as surrogate noninvasive biomarkers of renal tubular dysfunction. SUBJECTS AND METHODS: In this study, 40 ß-TM children and 30 healthy children were enrolled. Routine serum and urinary biochemical variables were determined. Urinary NTN-1 and CLU levels were measured using ELISA and their mRNA expression in PBMCs were assayed using real-time PCR. Serum TNF-α, MDA levels and GST activity were measured. RESULTS: Urinary NTN-1 and CLU concentrations and mRNA relative expression levels in PBMCs were significantly increased in ß-TM children relative to controls. Oxidative stress and inflammatory markers revealed significant elevation in ß-TM children compared to controls. The change in these parameters correlated significantly with other renal parameters. ROC curves analysis showed that urinary NTN-1 and CLU levels are of promising diagnostic performance. CONCLUSION: Our results suggest that NTN-1 and CLU are qualified as new noninvasive biomarker panels for early detection of renal injury in ß-TM children. Moreover, urinary NTN-1 is recommended as a precise one during the clinical practices.


Asunto(s)
Clusterina/orina , Enfermedades Renales/diagnóstico , Netrina-1/orina , Talasemia beta/orina , Adolescente , Biomarcadores/orina , Estudios de Casos y Controles , Niño , Preescolar , Clusterina/biosíntesis , Clusterina/genética , Creatinina/sangre , Diagnóstico Precoz , Ensayo de Inmunoadsorción Enzimática , Femenino , Ferritinas/sangre , Tasa de Filtración Glomerular , Glutatión Transferasa/sangre , Humanos , Enfermedades Renales/etiología , Enfermedades Renales/orina , Túbulos Renales/lesiones , Leucocitos Mononucleares/metabolismo , Masculino , Malondialdehído/sangre , Netrina-1/biosíntesis , Netrina-1/genética , Estrés Oxidativo , ARN Mensajero/biosíntesis , ARN Mensajero/sangre , ARN Mensajero/genética , Curva ROC , Reacción en Cadena en Tiempo Real de la Polimerasa , Factor de Necrosis Tumoral alfa/análisis , Talasemia beta/complicaciones , Talasemia beta/patología
2.
BMC Nephrol ; 21(1): 482, 2020 11 16.
Artículo en Inglés | MEDLINE | ID: mdl-33198660

RESUMEN

BACKGROUND: FGF23 controls serum l,25(OH)2D3 levels and phosphate homeostasis. This study evaluates the effects of ferritin on intact PTH, FGF23, and l,25(OH)2D3 in patients with major thalassemia. It also evaluates FGF23 changes in patients with hypoparathyroidism to clarify the interaction between FGF23 and PTH in the absence of proper PTH functioning in human. METHODS: In this case-control study, 25 major-beta thalassemia patients with hypoparathyroidism were age- and gender-matched with major-beta thalassemia patients having normal parathyroid function. Biochemical studies assessed the serum calcium, albumin, phosphorus, alkaline phosphatase, PTH, FGF23, 25(OH) D, 1,25(OH)2D3, ferritin, and the fractional excretion of phosphorous. RESULTS: FGF23 was higher in the patients with hypoparathyroidism than the controls (P = 0.002). The fractional excretion of phosphorous was lower in patients with hypoparathyroidism, despite the high level of FGF23 (P = 0.001). There was a correlation between serum 1,25(OH)2D3 and FGF23 with ferritin in the controls (P = < 0.001and P = < 0.001, respectively). CONCLUSIONS: The present study showed a strong positive correlation between serum ferritin and levels of FGF23 and 1,25(OH)2D3. We hypothesized that ferritin could have a stimulatory effect on the production of 1,25(OH)2D3. Moreover, a rise in FGF23 in patients with thalassemia, might be either associated with the stimulating effect of PTH and 1,25(OH)2D3, or directly related to the stimulating effect of ferritin.


Asunto(s)
Calcitriol/sangre , Ferritinas/sangre , Factores de Crecimiento de Fibroblastos/sangre , Hipoparatiroidismo/sangre , Vitamina D/sangre , Talasemia beta/sangre , Adulto , Estudios de Casos y Controles , Femenino , Factor-23 de Crecimiento de Fibroblastos , Humanos , Hipoparatiroidismo/complicaciones , Modelos Lineales , Masculino , Hormona Paratiroidea/sangre , Fosfatos/sangre , Fosfatos/orina , Talasemia beta/complicaciones , Talasemia beta/orina
3.
Kidney Blood Press Res ; 45(3): 455-466, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32434200

RESUMEN

INTRODUCTION: Renal dysfunction is a frequent complication in patients suffering from ß-thalassemia major (ß-TM). The aim of this study was to analyze the renal function and urine metabolomic profile of ß-TM patients undergoing transfusions and deferasirox (DFX) therapy, in order to better characterize and shed light on the pathogenesis of renal disease in this setting. METHODS AND SUBJECTS: 40 patients affected by ß-TM treated with DFX and 35 age- and gender-matched healthy controls were enrolled in the study. Renal function was assessed. Glomerular filtration rate (GFR) was estimated with CKD-EPI and Schwartz formula for adults and children, respectively. Renal tubular function and maximal urine concentration ability were tested. Urine specimens were analyzed by nuclear magnetic resonance spectroscopy to identify the urinary metabolite profiles. RESULTS: The study of renal function in ß-TM patients revealed normal estimated (e)GFR mean values and the albumin-to-creatinine ratio was <30 mg/g. The analysis of tubular function showed normal basal plasma electrolyte levels; 60% of patients presented hypercalciuria and many subjects showed defective urine concentration. Several amino acids, N-methyl compounds, and organic acids were overexcreted in the urine of thalassemic patients compared with controls. DISCUSSION: The major finding of this work is that ß-TM patients and controls exhibit different concentrations of some metabolites in the urine. Early recognition of urinary abnormalities may be useful to detect and prevent kidney damage.


Asunto(s)
Deferasirox/uso terapéutico , Urinálisis/métodos , Talasemia beta/tratamiento farmacológico , Talasemia beta/orina , Adulto , Deferasirox/farmacología , Femenino , Humanos , Masculino
4.
Expert Rev Hematol ; 12(4): 265-272, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30920854

RESUMEN

OBJECTIVES: Three iron chelators are used to treat transfusion-dependent beta-thalassemia: desferrioxamine (DFO), deferasirox (DFX), and deferiprone (DFP). Compliance is low for DFO as it cannot be administered orally. Combined administration of DFP and DFX is orally available, however, the therapeutic mechanism is unknown. This pilot study investigated the iron removal mechanisms of DFX and DFP treatment in patients with transfusion-dependent thalassemia major. METHODS: Each patient received three treatments sequentially: (1) DFX monotherapy, (2) DFP monotherapy, and (3) DFX/DFP combination therapy with a four-day washout period between each treatment. Urine and stool specimens were collected to determine the primary outcome of iron excretion volumes. RESULTS: The mean iron excretion was seven times higher after combination therapy with DFX and DFP. Monotherapies also increased excretions volumes, though to a significantly lesser degree. Combined administration of DFX and DFP achieves maximum iron removal in transfusion-dependent thalassemia major compared to monotherapy with either drug. CONCLUSIONS: We suggest combination therapy in chronic severe iron overload cases, especially for patients in poor compliance with DFO/DFP combination therapy or those exhibiting poor iron removal from DFX or DFP monotherapy.


Asunto(s)
Deferasirox/uso terapéutico , Deferiprona/uso terapéutico , Deferoxamina/uso terapéutico , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Talasemia beta/tratamiento farmacológico , Administración Oral , Adulto , Transfusión Sanguínea , Terapia por Quelación , Deferasirox/administración & dosificación , Deferiprona/administración & dosificación , Deferoxamina/administración & dosificación , Quimioterapia Combinada , Femenino , Humanos , Hierro/aislamiento & purificación , Hierro/orina , Quelantes del Hierro/administración & dosificación , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/orina , Masculino , Proyectos Piloto , Adulto Joven , Talasemia beta/complicaciones , Talasemia beta/orina
5.
Ann Hematol ; 98(5): 1101-1110, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30721337

RESUMEN

Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. This was a cross-sectional study in patients aged 15 years or older at Chiang Mai University Hospital. All patients had blood and 24-h urine collection test. We enrolled 112 thalassemia patients in which 67.0% were female, 64.3% had beta thalassemia/Hb E, 76.8% were transfusion dependent, and 59.8% were post splenectomy. The median age was 29 (16-58) years. Mean SUA was 6.7 ± 2.0 mg/dl and hyperuricemia (SUA > 6.8 mg/dl) was found in 47 cases (45.2%). Intact spleen (ORs 4.3, 95%CI 1.55-12.50, p = 0.01) and lower FEuric (ORs 2.08, 95%CI 1.35-3.33, p < 0.01) were associated with hyperuricemia significantly. Seven (6.3%) had gouty arthritis and nine (8%) had microscopic hematuria, one case being confirmed nephrolithiasis. The mean UUA excretion was 981.3 ± 335.0 mg/day and UUA hyperexcretion (> 700 mg/24 h) was found in 83.3%. UUA hyperexcretion patients had renal hyperfiltration 46%, glomerular dysfunction 84%, and tubular dysfunction 7.7%. From our study, hyperuricemia was found in approximately 40% of thalassemia patients but gouty arthritis occurred only in few patients (6%). This may be explained by urinary uric hyperexcretion which is found in over 80%. The significant risk factors for hyperuricemia were intact spleen and lower fraction excretion of uric acid.


Asunto(s)
Artritis Gotosa , Hematuria , Hiperuricemia , Talasemia beta , Adolescente , Adulto , Artritis Gotosa/sangre , Artritis Gotosa/etiología , Artritis Gotosa/orina , Estudios Transversales , Femenino , Tasa de Filtración Glomerular , Hematuria/sangre , Hematuria/etiología , Hematuria/orina , Humanos , Hiperuricemia/sangre , Hiperuricemia/etiología , Hiperuricemia/orina , Masculino , Persona de Mediana Edad , Esplenectomía , Ácido Úrico , Talasemia beta/sangre , Talasemia beta/complicaciones , Talasemia beta/cirugía , Talasemia beta/orina
6.
Hematology ; 22(4): 248-251, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-27809710

RESUMEN

BACKGROUND: Iron chelation therapy is one of the mainstays of the management of the patients with ß-thalassemia (BT) major. Deferasirox is an oral active iron chelating agent. Proteinuria is one of the potential renal adverse effects of deferasirox, and monthly follow-up for proteinuria is suggested by Food and Drug Administration and European Medicine Agency. METHODS: We aimed to investigate the necessity for monthly monitoring for proteinuria among patients with BT on deferasirox. A retrospective laboratory and clinic data review was performed for patients with BT major or intermedia who were treated with deferasirox chelation therapy. All patients were monitored for proteinuria for every 3 or 4 weeks after the initiation of deferasirox with serum creatinine and spot urine protein/creatinine ratios. RESULTS: The median follow-up time of the 37 (36 BT major and one BT intermedia) patients was 44 months. Seven patients (18.9%) developed significant proteinuria (ratio ≥0.8). Of the 1490 measurements, 12 tests (0.8%) were proteinuric. Urine proteinuria resolved in all of the patients during the follow-up. The risk of proteinuria was higher at ages below a cut-off point of 23 years (p = 0.019). Patients, who were on deferasirox at doses above a cut-off dose of 29 mg/kg/day, were found to have higher risk of proteinuria development (p = 0.004). CONCLUSION: Proteinuria resolves without any complication or major intervention according to our results. Potentially more risky groups (age below 23 years old and receivers above a dose of 29 mg/kg/day) might be suggested to be followed monthly, besides monitoring all of the patients.


Asunto(s)
Benzoatos/efectos adversos , Proteinuria/orina , Triazoles/efectos adversos , Talasemia beta/tratamiento farmacológico , Talasemia beta/orina , Adolescente , Adulto , Benzoatos/uso terapéutico , Niño , Preescolar , Deferasirox , Femenino , Humanos , Masculino , Proteinuria/inducido químicamente , Proteinuria/diagnóstico , Estudios Retrospectivos , Triazoles/uso terapéutico , Adulto Joven , Talasemia beta/sangre
7.
J Pediatr Hematol Oncol ; 39(1): e11-e14, 2017 01.
Artículo en Inglés | MEDLINE | ID: mdl-27548339

RESUMEN

BACKGROUND: ß-thalassemia is the most common heredity disease in Iran. Regular blood transfusion is critical to sustain life and normal growth. Deferasirox is an oral chelator. One of the side effects of the deferasirox is proteinuria. OBJECTIVES: This study aimed to investigate the safety of deferasirox on kidney function in diabetic and nondiabetic ß-thalassemia major patients. MATERIALS AND METHODS: In this cross-sectional study, 34 diabetic and 36 nondiabetic patients who take deferasirox (Exjade) 20 to 40 mg/kg/d were studied. Exclusion criteria included patient with renal failure, proteinuria, hepatitis B, hepatitis C, and the patients who refused to continue the study to the end. Subjects were divided into diabetic and nondiabetic groups. Spot urine protein/creatinine ratio, urinary analysis, alanine transaminase, aspartate transaminase, creatinine, fasting blood sugar, blood urea nitrogen, and serum ferritin were checked every 3 months. Patients were followed for a period of 1 year. RESULTS: In the ninth month after therapy there was a significant relationship in mean change of spot urine protein/creatinine ratio between diabetic and nondiabetic (P=0.011). Spot urine protein/creatinine ratio in diabetic and nondiabetic group was 0.19±0.18 and 0.1±0.05, respectively, which showed no significant relationship between the 2 groups at the end of study (P=0.162). CONCLUSION: The results of our study showed that consumption of deferasirox is safe, as there was no significant relationship between spot urine protein/creatinine ratio in diabetic and nondiabetic group. Deferasirox consumption is not associated with increased proteinuria in diabetic patients compared with nondiabetic group having only a transient proteinuria.


Asunto(s)
Benzoatos/efectos adversos , Diabetes Mellitus/etiología , Quelantes del Hierro/efectos adversos , Proteinuria/inducido químicamente , Triazoles/efectos adversos , Talasemia beta/complicaciones , Adolescente , Adulto , Benzoatos/uso terapéutico , Creatinina/orina , Estudios Transversales , Deferasirox , Deferiprona , Diabetes Mellitus/orina , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Sobrecarga de Hierro/etiología , Masculino , Piridonas/efectos adversos , Piridonas/uso terapéutico , Reacción a la Transfusión , Triazoles/uso terapéutico , Adulto Joven , Talasemia beta/terapia , Talasemia beta/orina
8.
Biomed Chromatogr ; 31(2)2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-27503066

RESUMEN

The present study was planned to optimize and validate an expedient reverse-phase high chromatography (RP-HPLC) based protocol for the analysis of deferoxamine (DFO) and ferrioxamine (FO) in urinary execration of patients suffering ß-thalassemia major. The optimized RP-HPLC method was found to be linear over the wide range of DFO and FO concentration (1-90 µg/mL) with appreciable recovery rates (79.64-97.30%) of quality controls at improved detection and quantitation limits and acceptable inter and intraday variability. Real-time analysis of DFO and FO in the urine of thalassemic patients (male and female) at different intervals of Desferal®(Novartis Pharmaceuticals Corporation) injection revealed DFO and FO excretion at significantly (p < 0) different rates. The maximum concentrations of DFO (76.7 ± 3.06 µg/mL) and FO (74.2 ± 3.25 µg/mL) were found in urine samples, collected after 6 h of drug infusion while the minimum levels of DFO (1.10 ± 0.12 µg/mL) and FO (2.97 ± 0.13 µg/mL) were excreted by patients after 24 h. The present paper offers balanced conditions for an expedient, reliable and quick determination of DFO and FO in urine samples.


Asunto(s)
Medios de Contraste/farmacocinética , Deferoxamina/orina , Compuestos Férricos/orina , Sideróforos/orina , Talasemia beta/orina , Adolescente , Niño , Preescolar , Cromatografía Líquida de Alta Presión/métodos , Cromatografía de Fase Inversa/métodos , Femenino , Humanos , Límite de Detección , Masculino
9.
Ren Fail ; 37(4): 607-13, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25656833

RESUMEN

BACKGROUND: The aim of this study was to investigate novel urinary biomarkers including N-acetyl-ß-D-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and liver-type fatty acid binding protein (L-FABP) in children with ß-thalassemia major (ß-TM). MATERIALS AND METHODS: Totally, 52 patients (29 boys, 23 girls) with ß-TM and 29 healthy controls (3-17 years) were included. Various demographic characteristics and blood transfusions/year, disease duration, and chelation therapy were recorded. Serum urea, creatinine, electrolytes, and ferritin and urinary creatinine, protein, calcium, phosphorus, sodium, potassium, and uric acid in first morning urine samples were measured and estimated glomerular filtration rate (eGFR) was calculated. Routine serum and urinary biochemical variables, urinary NAG to Creatinine (U(NAG/Cr)), U(NGAL/Cr), U(KIM-1/Cr), and U(L-FABP/Cr) ratios were determined. RESULTS: Patients had similar mean serum urea, creatinine and eGFR levels compared with controls (p > 0.05 for all). The mean urinary protein to creatinine (U(Protein/Cr)) ratio was significantly higher in patients compared to the healthy subjects (0.13 ± 0.09 mg/mg and 0.07 ± 0.04 mg/mg, respectively; p < 0.001). Significantly increased U(NAG/Cr) (0.48 ± 0.58 vs. 0.23 ± 0.16, p = 0.026) and U(NGAL/Cr) (22.1 ± 18.5 vs. 11.5 ± 6.17, p = 0.01) ratios were found in ß-TM patients compared with healthy controls. However, no differences were found in serum and urinary electrolytes or U(KIM-1/Cr) and U(L-FABP/Cr) ratios between patients and controls (p > 0.05). Significant correlations were found between urinary biomarkers and urinary electrolytes (p < 0.05). CONCLUSIONS: Our results suggest that urinary NAG and NGAL may be considered to be reliable markers to monitor renal injury in ß-TM patients.


Asunto(s)
Lesión Renal Aguda/etiología , Lesión Renal Aguda/orina , Talasemia beta/complicaciones , Talasemia beta/orina , Adolescente , Biomarcadores/orina , Niño , Preescolar , Estudios Transversales , Femenino , Humanos , Masculino
10.
Pediatr Hematol Oncol ; 30(8): 748-54, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24134694

RESUMEN

BACKGROUND: Beta thalassemia major is a lifelong transfusion-dependent disorder. Transfusion-dependent thalassemia patients are prone to develop renal dysfunction due to iron overload, chronic anemia, and/or chelation therapy. METHODS: In this prospective study, thalassemia patients who fitted inclusion and exclusion criteria received Deferasirox 20 mg/kg/day. A complete biochemistry analysis of serum and 24-hour-urine specimens was performed before and after treatment. Estimated glomerular filtration rate (eGFR), Fractional excretion of sodium (FENA), potassium (FEK), uric acid (FEUA), and the maximum ratio of tubular reabsorption of phosphorus to eGFR (TmP/GFR) at baseline and after treatment was calculated and compared. RESULTS: A total of 30 patients with mean age of 4.9 ± 3.2 years were recruited. The mean serum creatinine increased significantly after 6 months of treatment (0.54 ± 0.08 vs. 0.67 ± 0.16, P < .001) while eGFR was decreased (104.36 ± 19.62 vs. 86.00 ± 16.92, P < .001). Mean potassium level in serum was increased after treatment, while serum calcium, magnesium, and uric acid levels decreased significantly (P > .05). A significant increase was confirmed for mean urinary ß2-microglobulin (ß2-MG), protein, uric acid, calcium, and magnesium (P > .05). CONCLUSION: Our findings highlighted tubular nephropathy induced by Deferasirox in patients with beta thalassemia, and confirmed the necessity for diligent monitoring of renal function in thalassemia patients receiving Deferasirox.


Asunto(s)
Benzoatos/efectos adversos , Quelantes del Hierro/efectos adversos , Sobrecarga de Hierro/tratamiento farmacológico , Enfermedades Renales/inducido químicamente , Triazoles/efectos adversos , Talasemia beta/terapia , Adolescente , Benzoatos/administración & dosificación , Transfusión Sanguínea , Niño , Preescolar , Creatinina/sangre , Creatinina/orina , Deferasirox , Femenino , Tasa de Filtración Glomerular/efectos de los fármacos , Humanos , Quelantes del Hierro/administración & dosificación , Sobrecarga de Hierro/sangre , Sobrecarga de Hierro/etiología , Sobrecarga de Hierro/orina , Enfermedades Renales/sangre , Enfermedades Renales/fisiopatología , Enfermedades Renales/orina , Masculino , Metales/sangre , Metales/orina , Estudios Prospectivos , Triazoles/administración & dosificación , Talasemia beta/sangre , Talasemia beta/fisiopatología , Talasemia beta/orina
11.
J Trace Elem Med Biol ; 27(2): 109-11, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23164519

RESUMEN

Zinc which is an essential element has very important effects on growth and immune system in patients with thalassemia major (TM). The effects of two oral iron chelator agents, desferrioxamine (DFO) and deferiprone (DFP), on zinc levels were investigated in previous studies and they were found to cause zinc deficiency. Zinc level alteration by the new chelator deferasirox (DFX) is not present in the literature. The aim of this study was to examine the effects of different oral chelators on serum and urine zinc levels in TM patients. Zinc levels are compared in the patients who received different chelators: only DFX, combined chelation with DFO plus DFP and the healthy control group. A total of 56 patients with TM were involved in this study: 39 patients received only DFX and 17 patients were given combined treatment DFO+DFP between August 2008 and August 2009. In addition, a control group was established from the healthy population. Blood was taken from all the patients for serum zinc levels and 24hour-urine samples were collected for urine zinc levels. Serum zinc levels were found to be 64.8±14.8µg/dL in DFX group and 66.5±15.1µg/dL in DFO+DFP group. These levels were statistically lower than that in the control group (149±54.3µg/dL) (p<0.05), but there was no statistically difference between the two different chelation groups (p>0.05). The urine zinc levels of DFX and DFO+DFP group were 662.2±428.2µg/day and 1182.3±980.3µg/day respectively (p<0.05). Urinary zinc excretion in the chelation groups (DFX and DFO+DFP) was significantly higher than the control group (395.1±208.9µg/day) (p<0.05). As a conclusion, the new chelation agent, DFX, also leads to zinc deficiency, though its urinary zinc excretion is lower. New studies are required to examine the effects of DFX on zinc extensively. Zinc levels of patients with TM should be followed up regularly and zinc supply should be given at early ages.


Asunto(s)
Quelantes del Hierro/uso terapéutico , Zinc/sangre , Zinc/orina , Talasemia beta/sangre , Talasemia beta/tratamiento farmacológico , Adolescente , Benzoatos/uso terapéutico , Deferasirox , Deferiprona , Deferoxamina/uso terapéutico , Demografía , Femenino , Humanos , Masculino , Piridonas/uso terapéutico , Triazoles/uso terapéutico , Adulto Joven , Talasemia beta/orina
12.
Pharmacology ; 90(1-2): 88-94, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22759897

RESUMEN

Dose-related pharmacokinetics and urinary iron excretion (UIE) of an orally active iron chelator, deferiprone (L1), was investigated in 12 severe ß-thalassemia/hemoglobin E patients. The patients received two single doses of 25 and 50 mg/kg with a 2-week washout period. Deferiprone was rapidly absorbed and reached maximum concentration (C(max)) within 1 h after administration. Pharmacokinetic parameters including C(max) and area under concentration time curve from time zero to infinity (AUC(0-∞)) as well as urinary excretion of non-conjugated and glucuronide-conjugated deferiprone (L1 and L1-G) increased proportionally with the dose of deferiprone. A constant ratio of AUC(0-∞) of L1-G to L1 and a percentage of urinary excretion of L1-G indicated that increasing the dosage does not influence deferiprone biotransformation. Longer terminal elimination half-lifeand higher volume of distribution of L1 were observed with the high dose and correlated with deferiprone-chelated iron in serum. Unexpectedly, UIE did not show a linear relationship with the increased dose of deferiprone. The correlation between UIE and creatinine clearance suggested the possibility of L1-iron complex redistribution in patients with renal impairment treated with high-dose deferiprone.


Asunto(s)
Quelantes del Hierro/farmacocinética , Hierro/orina , Piridonas/farmacocinética , Talasemia beta/orina , Adolescente , Adulto , Área Bajo la Curva , Deferiprona , Femenino , Glucurónidos/orina , Hemoglobina E , Humanos , Masculino , Persona de Mediana Edad , Piridonas/orina , Adulto Joven
13.
PLoS One ; 7(5): e36425, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22586470

RESUMEN

Hepcidin is a regulatory hormone that plays a major role in controlling body iron homeostasis. Circulating factors (holotransferrin, cytokines, erythroid regulators) might variably contribute to hepcidin modulation in different pathological conditions. There are few studies analysing the relationship between hepcidin transcript and related protein expression profiles in humans. Our aims were: a. to measure hepcidin expression at either hepatic, serum and urinary level in three paradigmatic iron overload conditions (hemochromatosis, thalassemia and dysmetabolic iron overload syndrome) and in controls; b. to measure mRNA hepcidin expression in two different hepatic cell lines (HepG2 and Huh-7) exposed to patients and controls sera to assess whether circulating factors could influence hepcidin transcription in different pathological conditions. Our findings suggest that hepcidin assays reflect hepatic hepcidin production, but also indicate that correlation is not ideal, likely due to methodological limits and to several post-trascriptional events. In vitro study showed that THAL sera down-regulated, HFE-HH and C-NAFLD sera up-regulated hepcidin synthesis. HAMP mRNA expression in Huh-7 cells exposed to sera form C-Donors, HFE-HH and THAL reproduced, at lower level, the results observed in HepG2, suggesting the important but not critical role of HFE in hepcidin regulation.


Asunto(s)
Péptidos Catiónicos Antimicrobianos/metabolismo , Hemocromatosis , Sobrecarga de Hierro , Hierro/metabolismo , Talasemia beta , Adulto , Anciano , Péptidos Catiónicos Antimicrobianos/sangre , Péptidos Catiónicos Antimicrobianos/orina , Biopsia , Citocinas/sangre , Citocinas/orina , Regulación de la Expresión Génica , Hemocromatosis/sangre , Hemocromatosis/orina , Proteína de la Hemocromatosis , Células Hep G2 , Hepcidinas , Antígenos de Histocompatibilidad Clase I/genética , Antígenos de Histocompatibilidad Clase I/metabolismo , Humanos , Sobrecarga de Hierro/sangre , Sobrecarga de Hierro/patología , Sobrecarga de Hierro/orina , Hígado/metabolismo , Hígado/patología , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Persona de Mediana Edad , ARN Mensajero/genética , ARN Mensajero/metabolismo , Transferrina/orina , Talasemia beta/sangre , Talasemia beta/orina
14.
Haematologica ; 97(6): 835-41, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22180427

RESUMEN

BACKGROUND: Plasma non-transferrin bound iron refers to heterogeneous plasma iron species, not bound to transferrin, which appear in conditions of iron overload and ineffective erythropoiesis. The clinical utility of non-transferrin bound iron in predicting complications from iron overload, or response to chelation therapy remains unproven. We undertook carefully timed measurements of non-transferrin bound iron to explore the origin of chelatable iron and to predict clinical response to deferiprone. DESIGN AND METHODS: Non-transferrin bound iron levels were determined at baseline and after 1 week of chelation in 32 patients with thalassemia major receiving deferiprone alone, desferrioxamine alone, or a combination of the two chelators. Samples were taken at baseline, following a 2-week washout without chelation, and after 1 week of chelation, this last sample being taken 10 hours after the previous evening dose of deferiprone and, in those receiving desferrioxamine, 24 hours after cessation of the overnight subcutaneous infusion. Absolute or relative non-transferrin bound iron levels were related to transfusional iron loading rates, liver iron concentration, 24-hour urine iron and response to chelation therapy over the subsequent year. RESULTS: Changes in non-transferrin bound iron at week 1 were correlated positively with baseline liver iron, and inversely with transfusional iron loading rates, with deferiprone-containing regimens but not with desferrioxamine monotherapy. Changes in week 1 non-transferrin bound iron were also directly proportional to the plasma concentration of deferiprone-iron complexes and correlated significantly with urine iron excretion and with changes in liver iron concentration over the next 12 months. CONCLUSIONS: The widely used assay chosen for this study detects both endogenous non-transferrin bound iron and the iron complexes of deferiprone. The week 1 increments reflect chelatable iron derived both from liver stores and from red cell catabolism. These increments correlate with urinary iron excretion and the change in liver iron concentration over the subsequent year thus predicting response to deferiprone-containing chelation regimes. This clinical study was registered at clinical.trials.gov with the number NCT00350662.


Asunto(s)
Terapia por Quelación , Deferoxamina/uso terapéutico , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Piridonas/uso terapéutico , Talasemia beta/tratamiento farmacológico , Adolescente , Proteínas Sanguíneas/metabolismo , Transfusión Sanguínea , Niño , Deferiprona , Deferoxamina/administración & dosificación , Esquema de Medicación , Humanos , Hierro/sangre , Hierro/orina , Quelantes del Hierro/administración & dosificación , Sobrecarga de Hierro/sangre , Sobrecarga de Hierro/orina , Hígado/metabolismo , Estudios Longitudinales , Unión Proteica , Piridonas/administración & dosificación , Adulto Joven , Talasemia beta/sangre , Talasemia beta/orina
15.
Pediatr Hematol Oncol ; 28(6): 509-16, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21762013

RESUMEN

Recent evidence supports the presence of renal dysfunction even among young patients with ß-thalassemia major. However, the possible genetic contribution has never been investigated. The aim of this study was to correlate the presence of Fok-I polymorphism of the vitamin D receptor gene with abnormal levels of early markers of renal impairment in children and young adults with thalassemia. Thirty-four patients (19 male and 15 female) with ß-thalassemia major on conventional treatment, with a mean decimal age of 14.62 ± 5.47 years (range: 5-22 years), were included in the study. Markers of renal function were determined in serum and in urine and patients were genotyped for Fok-I gene polymorphism. Genotype frequencies were similar to those previously reported for other populations: 47.06% of the patients were homozygous for the F allele, 41.18% were heterozygous, and 11.76% were homozygous for the f allele. A considerable number of patients demonstrated impaired renal function with increased serum cystatin C levels (29.41%), glomerular dysfunction with proteinuria (68%), as well as significant tubulopathy with hypercalciuria (73.08%), and increased levels of urinary ß(2)-microglobulin (29.41%). When patients were stratified according to Fok-I polymorphism, a significantly higher prevalence of abnormally increased serum levels of cystatin C was observed in patients being homozygous for the f allele (75%) compared with those being heterozygous (Ff) or homozygous for the F allele (14.29% and 31.25%, respectively, P = .02). Further studies are needed to confirm these preliminary results and elucidate the possible mechanisms involved.


Asunto(s)
Alelos , Frecuencia de los Genes , Enfermedades Renales/genética , Polimorfismo de Longitud del Fragmento de Restricción , Receptores de Calcitriol/genética , Talasemia beta/genética , Adolescente , Adulto , Biomarcadores/sangre , Biomarcadores/orina , Calcio/orina , Niño , Preescolar , Cistatina C/sangre , Femenino , Genotipo , Mesangio Glomerular/metabolismo , Humanos , Enfermedades Renales/sangre , Enfermedades Renales/orina , Masculino , Proteinuria/sangre , Proteinuria/orina , Receptores de Calcitriol/metabolismo , Microglobulina beta-2/orina , Talasemia beta/sangre , Talasemia beta/orina
16.
Hematology ; 16(4): 249-54, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21756543

RESUMEN

PURPOSE: In this study, the relationship between glomerular and tubular function and creatinine, glomerular filtration rate (GFR) and urine NAG in thalassemia major patients aged 7-16 years was investigated. DESIGN AND SETTING: This is a case-control study comprising 280 individuals [144 (51·4%), males; 136 (48·6%), females]. MATERIALS AND METHODS: Patients were divided in groups of 14 individuals and age groups of 7-16 years. Sodium excretion fraction, fraction excretion of potassium, calcium-to-creatinine and uric acid-to-creatinine ratios, and duration of specific blood transfusion were determined in all age groups receiving deferoxamine. RESULTS: GFR decreased with increasing age, but the correlation was not statistically significant. There was no significant correlation between the ferritin levels and the GFR changes. The mean value of NAG activity between thalassemic patients and controls has no significant difference. The difference in mean age of the groups with high NAG activity and normal NAG activity was statistically significant. Thirty-seven patients (52·1%) in the group with normal NAG activity, and 45 patients (6·25%) in the group with NAG activity above normal were observed with uricosuric effects with no significant difference. Four patients (6·9%) in the group with normal NAG activity and six patients (7·3%) in the group with NAG activity above normal were shown to have hematuria with no significant difference. The results show that the increase in serum ferritin is significantly correlated with the increase in NAG activity (P<0·001, r = 0·2). Of patients with normal NAG activity 1 (1·7%) and with NAG activity higher than normal, 13 (15·9%) cases experienced hypercalciuria that significant difference was existing. The data also indicated that the NAG changes do not correlate with GFR changes. CONCLUSION: The results showed that kidney dysfunction in thalassemia increases with increasing age, duration, and levels of blood transfusion and hypercalciuria. It is therefore recommended that the presence of severe renal dysfunction in thalassemic patients should be investigated using sensitive and specific tests, mainly NAG, to prevent progress towards the complications.


Asunto(s)
Enfermedades Renales/fisiopatología , Riñón/fisiopatología , Talasemia beta/fisiopatología , Acetilglucosaminidasa/orina , Adolescente , Transfusión Sanguínea/métodos , Estudios de Casos y Controles , Niño , Creatinina/orina , Femenino , Humanos , Riñón/patología , Enfermedades Renales/patología , Enfermedades Renales/orina , Masculino , Prevalencia , Estudios Prospectivos , Proteinuria/orina , Talasemia beta/patología , Talasemia beta/orina
17.
Acta Haematol ; 123(3): 148-52, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20185899

RESUMEN

There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction. The aim of the present study was to investigate renal involvement in young thalassemia patients, using both conventional and early markers of renal dysfunction, and to correlate findings to iron chelation therapy. Forty-two patients aged 4-23 years were studied and, for analysis purposes, were divided into two groups based on chelation therapy (group A receiving deferasirox and group B receiving deferoxamine and deferiprone combination therapy). In addition to conventional renal biochemistries, creatinine clearance, estimated glomerular filtration rate, serum cystatin C (Cys C), fractional excretion of sodium, tubular phosphorus reabsorption and urine calcium, protein, beta(2)-microglobulin (beta(2)-MG) and glucose levels were measured. A considerable number of patients demonstrated impaired renal function with elevated Cys C levels (36%), glomerular dysfunction with proteinuria (24%) and tubulopathy with hypercalciuria (35.5%) and elevated excretion of beta(2)-MG (33.5%). Renal involvement seems to be present even in young patients with beta-thalassemia, therefore, routine use of early markers of renal dysfunction is recommended. Further studies are needed in order to investigate the role of new chelators in tubular function parameters.


Asunto(s)
Benzoatos/efectos adversos , Deferoxamina/efectos adversos , Quelantes del Hierro/efectos adversos , Enfermedades Renales/complicaciones , Piridonas/efectos adversos , Triazoles/efectos adversos , Talasemia beta/tratamiento farmacológico , Adolescente , Adulto , Benzoatos/uso terapéutico , Biomarcadores/sangre , Biomarcadores/orina , Terapia por Quelación/efectos adversos , Niño , Preescolar , Cistatina C/sangre , Deferasirox , Deferiprona , Deferoxamina/uso terapéutico , Quimioterapia Combinada , Diagnóstico Precoz , Femenino , Humanos , Hipercalciuria , Quelantes del Hierro/uso terapéutico , Enfermedades Renales/sangre , Enfermedades Renales/inducido químicamente , Enfermedades Renales/orina , Pruebas de Función Renal , Masculino , Proteinuria , Piridonas/uso terapéutico , Triazoles/uso terapéutico , Adulto Joven , Microglobulina beta-2/orina , Talasemia beta/sangre , Talasemia beta/complicaciones , Talasemia beta/orina
18.
Am J Hematol ; 84(4): 231-3, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19291727

RESUMEN

Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E4 (LTE4), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso-occlusion, we tested the hypothesis that LTE4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode (P < 0.001). These data further support a contribution of CysLTs to the process of vaso-occlusion.


Asunto(s)
Anemia de Células Falciformes/orina , Leucotrieno E4/orina , Dolor/orina , Acetatos/farmacología , Acetatos/uso terapéutico , Adolescente , Adulto , Anemia de Células Falciformes/complicaciones , Antiasmáticos/farmacología , Antiasmáticos/uso terapéutico , Asma/complicaciones , Asma/tratamiento farmacológico , Biomarcadores , Niño , Estudios de Cohortes , Ciclopropanos , Femenino , Hemoglobina Fetal/genética , Enfermedad de la Hemoglobina C/genética , Enfermedad de la Hemoglobina C/orina , Heterocigoto , Hospitalización/estadística & datos numéricos , Humanos , Isquemia/etiología , Isquemia/orina , Antagonistas de Leucotrieno/farmacología , Antagonistas de Leucotrieno/uso terapéutico , Masculino , Dolor/etiología , Quinolinas/farmacología , Quinolinas/uso terapéutico , Estudios Retrospectivos , Rasgo Drepanocítico/genética , Rasgo Drepanocítico/orina , Sulfuros , Adulto Joven , Talasemia beta/genética , Talasemia beta/orina
19.
Haematologica ; 92(12): 1599-606, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18055982

RESUMEN

BACKGROUND AND OBJECTIVES: The aim of this prospective, randomized, 1-year study was to compare the efficacy and safety of oral deferiprone (DFP) with those of combinations of parenteral desferrioxamine (DFO) with oral DFP. DESIGN AND METHODS: A total of 24 patients with thalassemia major were randomized to receive one of the following two treatments; DFP given at a daily dose of 75 mg/kg in combination with DFO (40-50 mg/kg twice weekly) (n=12) or as single agent (n=12). In addition, 12 patients treated with 40-50 mg/kg DFO 5 days weekly were included as a reference group without randomization. Changes in liver iron concentration (LIC) and serum ferritin (SF) were assessed; total iron excretion (TIE), urinary iron excretion (UIE) and iron balance were calculated. Cardiac function and toxicity were also examined. DESIGN AND METHODS: SF and LIC were significantly reduced after 1 year of combination therapy (p=0.01 and 0.07, respectively). A decrease of LIC was observed in all but one patient (87.5%) following the combination therapy but in only 42% of patients treated with DFP monotherapy. In the DFO reference group, a statistically significant decrease in LIC (p=0.01) associated with a substantial decrease in SF (p=0.08) was observed after 1 year. The combination regimen resulted in greater TIE compared to DFP monotherapy (p=0.08) and was the regimen associated with the highest iron balance compared to DFP monotherapy (p=0.04) or standard DFO treatment (p=0.006). INTERPRETATIONS AND CONCLUSIONS: The addition of subcutaneous DFO twice weekly to oral DFP 75 mg/kg is a highly efficacious and safe chelation therapy providing superior chelation activity to that of DFP and likely has an efficacy profile comparable to that of standard DFO.


Asunto(s)
Deferoxamina/administración & dosificación , Piridonas/administración & dosificación , Sideróforos/administración & dosificación , Talasemia beta/tratamiento farmacológico , Adolescente , Adulto , Niño , Deferiprona , Femenino , Ferritinas/sangre , Humanos , Hierro/sangre , Hierro/orina , Hígado/metabolismo , Masculino , Factores de Tiempo , Talasemia beta/sangre , Talasemia beta/orina
20.
Br J Haematol ; 138(3): 374-81, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-17614825

RESUMEN

The most widely used drug for iron chelation is deferoxamine (DFO) mesylate. While effective in promoting iron excretion, it requires prolonged daily infusions, often resulting in poor compliance. A clinical trial was conducted using starch-conjugated DFO (S-DFO; 40SD02), a high-molecular-weight iron chelator possessing prolonged vascular retention. Single doses of S-DFO were infused intravenously into groups of four transfusion-dependent patients with beta-thalassaemia at doses of 150, 300, 600 and 900 mg/kg. Urinary iron excretion and various pharmacologic parameters were evaluated for 1 week and safety for 3 weeks. No drug-related effects were observed on clinical chemistries, haematological and coagulation parameters, urinalyses, vital signs or electrocardiograms. Drug-related adverse events were limited to four urticarial reactions, none requiring termination of the infusion. The drug stimulated clinically significant urinary iron excretion, with the highest dose (900 mg/kg) inducing excretion of 1.31 mg of iron/kg (range 0.79-1.90 mg/kg) over 1 week, with residual iron-binding capacity present in the plasma for over 6 d. In summary, treatment with S-DFO, administered weekly, has the potential to achieve iron balance in the poorly compliant patient.


Asunto(s)
Terapia por Quelación/métodos , Deferoxamina/uso terapéutico , Quelantes del Hierro/uso terapéutico , Talasemia beta/tratamiento farmacológico , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Infusiones Intravenosas , Hierro/sangre , Hierro/orina , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Talasemia beta/sangre , Talasemia beta/orina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...